Pneumonia Risk Factors: Doctors recommend getting the pneumonia vaccine, also known as the pneumococcal vaccine. This vaccine ...

In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...

After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at ...

The inequalities gap in uptake rates of pneumococcal vaccine for vulnerable groups is widening and simplifying the vaccine schedule has not reduced this, researchers from the University of Liverpool ...

Vaccine uptake data has been examined to assess the impact of moving from a '2+1' to a '1+1' Pneumococcal Conjugate Vaccine (PCV) dose schedule on vaccine coverage and health inequalities among ...

1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

Utilizing pneumococcal conjugate vaccines (PCVs) could save almost 700,000 children's lives between the time of their introduction to the year 2030, according to a new modeling study. This would be ...

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...